These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601 [TBL] [Abstract][Full Text] [Related]
6. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34 Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Roeker LE; Dreger P; Brown JR; Lahoud OB; Eyre TA; Brander DM; Skarbnik A; Coombs CC; Kim HT; Davids M; Manchini ST; George G; Shah N; Voorhees TJ; Orchard KH; Walter HS; Arumainathan AK; Sitlinger A; Park JH; Geyer MB; Zelenetz AD; Sauter CS; Giralt SA; Perales MA; Mato AR Blood Adv; 2020 Aug; 4(16):3977-3989. PubMed ID: 32841336 [TBL] [Abstract][Full Text] [Related]
8. Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. Chhabra S; Szabo A; Glisch C; George G; Narra RK; Harrington A; Jerkins JH; D'Souza A; Dhakal B; Pasquini MC; Hamadani M; Hari PN Biol Blood Marrow Transplant; 2020 Jul; 26(7):1288-1297. PubMed ID: 32135202 [TBL] [Abstract][Full Text] [Related]
9. Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia. Chen GL; Liu H; Zhang Y; Thomas J; Ross M; Wang ES; Block AW; Sait S; Deeb G; Wallace P; Wetzler M; Hahn T; McCarthy PL Biol Blood Marrow Transplant; 2014 Sep; 20(9):1369-74. PubMed ID: 24867777 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group. Gołos A; Gil L; Puła B; Boguradzki P; Hałaburda K; Sawicki W; Sobczyk-Kruszelnicka M; Helbig G; Dybko J; Jurczyszyn A; Dębek S; Warzocha K; Jamroziak K Adv Med Sci; 2020 Sep; 65(2):429-436. PubMed ID: 32919120 [TBL] [Abstract][Full Text] [Related]
12. Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis. Eftychidis I; Sakellari I; Anagnostopoulos A; Gavriilaki E Expert Rev Hematol; 2021 Sep; 14(9):831-840. PubMed ID: 34388057 [TBL] [Abstract][Full Text] [Related]
13. Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. Freyer CW; Gier S; Moyer ME; Berryman N; Carulli A; Ganetsky A; Timlin C; Babushok DV; Frey NV; Gill SI; Hexner EO; Loren AW; Mangan JK; Martin ME; McCurdy S; Perl AE; Smith J; Luger SM; Stadtmauer EA; Porter DL Transplant Cell Ther; 2021 May; 27(5):431.e1-431.e8. PubMed ID: 33965188 [TBL] [Abstract][Full Text] [Related]
14. Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation. Freyer CW; Fradley M; Madnick D; Carver JR; Frey NV; Gill SI; Ky B; Luger SM; Martin ME; McCurdy SR; O'Quinn R; Perl AE; Stadtmauer EA; Loren AW Transplant Cell Ther; 2021 Nov; 27(11):934.e1-934.e6. PubMed ID: 34339867 [TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
16. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients. Solh MM; Bashey A; Solomon SR; Morris LE; Zhang X; Brown S; Holland HK Bone Marrow Transplant; 2018 May; 53(5):576-583. PubMed ID: 29335633 [TBL] [Abstract][Full Text] [Related]
17. Neurological adverse events post allogeneic hematopoietic cell transplantation: major determinants of morbidity and mortality. Sakellari I; Gavriilaki E; Papagiannopoulos S; Gavriilaki M; Batsis I; Mallouri D; Vardi A; Constantinou V; Masmanidou M; Yannaki E; Smias C; Geroukis T; Kazis D; Kimiskidis V; Anagnostopoulos A J Neurol; 2019 Aug; 266(8):1960-1972. PubMed ID: 31087160 [TBL] [Abstract][Full Text] [Related]